MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Favipiravir

CAS No. : 259793-96-9

MCE 站：Favipiravir

产品活性：Favipiravir (T-705) 是一种病毒 RNA 聚合酶 (RNA polymerase) 抑制剂，可转变为其活性形式 Favipiravir-ribofuranosyl-5′-triphosphate (RTP)。Favipiravir-RTP 抑制流感病毒RNA依赖性的RNA聚合酶 (RdRP) 活性，IC₅₀ 为 341 nM。

研究领域：Cell Cycle/DNA Damage  |  Anti-infection

作用靶点：DNA/RNA Synthesis  |  Influenza Virus  |  SARS-CoV

In Vitro: Favipiravir (T 705) is an antiviral drug that selectively inhibits the RNA-dependent RNA polymerase of influenza virus. Favipiravir (T 705) is a novel antiviral compound that selectively and potently inhibits the RNA-dependent RNA polymerase (RdRP) of influenza and many other RNA viruses. Favipiravir-RTP does not inhibit the human DNA polymerase α, β or γ with IC₅₀>1 mM. The IC₅₀ for the human RNA polymerase II is 905 μM; Favipiravir is therefore 2,650 times more selective for the influenza virus RdRP, consistent with the lack of inhibition of host-cell DNA and RNA synthesis. Favipiravir (T 705) acts as a pro-drug, its cytotoxicity is expected to be cell-line dependent. Favipiravir inhibits in a dose-dependent manner MNV-induced CPE (EC₅₀: 250±11 μM) and MNV RNA synthesis in cell culture (EC₅₀:124±42 μM). Despite this rather modest antiviral activity, Favipiravir (T 705) is able to completely inhibit norovirus replication at a concentration of 100 μg/mL, which is a concentration that has little or no adverse effect on the host cell (cell viability >80%).

In Vivo: Favipiravir (T 705) (30 mg/kg/day, orally) improves survival compare to placebo. Favipiravir (T 705) also provides significant protection against the A/Duck/MN/1525/81(H5N1) virus at a dose of 33 mg/kg/day or more, regardless of the number of daily doses. When given 4 times a day, all mice survive.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Cell Cycle/DNA Damage Compound Library  |  FDA-Approved Drug Library  |  Antiviral Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Anti-COVID-19 Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Cycloheximide  |  Chloroquine  |  Acetylcysteine  |  Dexamethasone  |  Oxaliplatin  |  Gemcitabine  |  U0126-EtOH  |  Actinomycin D  |  Mitomycin C  |  Tunicamycin  |  Bleomycin sulfate  |  Hydroxychloroquine sulfate  |  Carboplatin  |  Cytarabine  |  Vadimezan  |  Curcumin  |  Methotrexate  |  Streptozocin  |  Imatinib  |  Anisomycin  |  Aloxistatin  |  Camptothecin  |  Thapsigargin  |  Aprotinin  |  Imiquimod  |  Camostat mesylate  |  Oseltamivir acid  |  Fludarabine

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。